Goldman Sachs Downgrades Ultragenyx Pharma (RARE) to Neutral

March 24, 2026 2:32 AM

Goldman Sachs analyst Salveen Richter downgraded Ultragenyx Pharma (NASDAQ: RARE) from Buy to Neutral with a price target of $25.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found